Pharma Mag publishes an article by Paul Ranson, Sharmela Thevarajaha and Antonina Nijran which offers practical advice to pharmaceutical companies seeking to manage their risks in relation to the recently enacted Bribery Act
Pharma Mag
December 6, 2011
Paul Ranson, a partner in Fasken Martineau DuMoulin LLP and Fasken Martineau LLP (London), is a member of the Firm's Technology and Intellectual Property practice group. He also leads the Firm's Life Sciences practice group in London.
Sharmela Thevarajaha and
Antonina Nijran are both Associates at Fasken Martineau LLP (London). They are members of the Firm's Technology and Intellectual Property group, as well as its Life Sciences group.
Excerpt
The pharma industry is not immune to the recently enforced Bribery Act 2010. The authors provide some practical advice for pharmaceutical companies seeking to manage their risks in relation to the corporate offence with the legislation.
The Bribery Act 2010 (the "Act") came into force in July 2011 and brought with it wide-ranging powers to enable UK prosecutors to combat bribery and corruption. Significantly for companies, the Act also introduces a new corporate offence, which will only be defensible if adequate procedures to prevent bribery and corruption have been put in place.